@article{2c0bf1e9b51c4849a1e23bfbd79832e0,
title = "Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?",
author = "Matthias Totzeck and Esther Lutgens and Neilan, \{Tomas G.\}",
note = "Funding Information: Conflict of interest: M.T. has received personal funding and advisory fees from Bayer Vital, Astra Zeneca, Daiichi Sankyo, and Bristol Myers Squibb. T.G.N. has received advisory fees from Parexel, BMS, H3 Biomedicine, AbbVie, and Intrinsic Imaging, and grant funding from Astra Zeneca. E.L. has no conflicts to declare. Funding Information: This work was supported by the National Institutes of Health/National Heart, Lung, Blood Institute [T32HL076136; R01HL137562-, R01HL130539, and K24HL150238 to T.G.N.]. T.G.N.was also supported, in part, through a kind gift from A. Curtis Greer and Pamela Kohlberg. The figure was produced using Servier Medical Art. ",
year = "2021",
month = apr,
day = "21",
doi = "10.1093/eurheartj/ehaa959",
language = "English (US)",
volume = "42",
pages = "1632--1635",
journal = "European heart journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "16",
}